EGFR and esophageal squamous cell carcinoma: In a phase 2 trial of icotinib, which is another EGFR TKI, the PFS and OS in previously treated metastatic ESCC patients with EGFR overexpression or EGFR gene amplification were 52 days and 153 days, respectively.11